Nick Keur, Emmanouil Stylianakis, Isis Ricaño-Ponce, Vassiliki Rapti, Haralampos Milionis, Simeon Metallidis, Georgios Adamis, Archontoula Fragkou, Aggeliki Rapti, Pierluigi del Vecchio, Eleni Florou, Ioannis Kalomenidis, Georgios Chrysos, Andrea Angheben, Ilias Kainis, Konstantina Iliopoulou, Francesco Castelli, Francesco Saverio Serino, Agamemnon Bakakos, Emanuele Nicastri, Maria Dafni, Sofia Ioannou, Lorenzo Dagna, Katerina Dimakou, Glykeria Tzatzagou, Maria Chini, Matteo Bassetti, Vasileios Kotsis, George Tsoukalas, Carlo Selmi, Evangelos Siarkos, Michael Samarkos, Michael Doumas, Aikaterini Masgala, Ilias Papanikolaou, Aikaterini Argyraki, Karolina Akinosoglou, Konstantinos Syrigos, Styliani Sympardi, Periklis Panagopoulos, George N. Dalekos, Mihai G. Netea, Evangelos J. Giamarellos-Bourboulis and Vinod Kumar
EBioMedicine. 2026 Nov 18;134:106561
DOI: 10.1016/j.ebiom.2026.106561Download pdf
Funding
The trial was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) and funded by Swedish Orphan Biovitrum AB (Sobi).
Keywords: Anakinra; Proteomics; Sepsis; Severe COVID-19; Severe respiratory failure
Related study: SAVE-MORE
